|Day Low/High||6.16 / 6.50|
|52 Wk Low/High||3.28 / 7.29|
Three small-cap biotechs with attractive risk/reward profiles.
If you want to trade, you have to maintain short timeframes and be ready to flip.
Company highlights its T cell-Directed Genital Herpes and Neoantigen Cancer Vaccine Candidates in two oral presentations
Dr. Mayer brings significant depth of experience in global clinical drug development
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
Genocea Chief Scientific Officer honored for innovation in development of novel immunotherapies
- GEN-003 Phase 2b Viral Shedding Data Expected in September 2016 -
Trade-Ideas LLC identified Genocea Biosciences (GNCA) as a weak on high relative volume candidate
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.